Advertisement
Loading...

Izotropic Corporation

IZOZFPNK
Healthcare
Medical - Diagnostics & Research
$0.15
$-0.04(-21.01%)
U.S. Market opens in 12h 37m
Advertisement

Izotropic Corporation Fundamental Analysis

Izotropic Corporation (IZOZF) shows moderate financial fundamentals with a PE ratio of -5.42, profit margin of 0.00%, and ROE of 48.18%. The company generates N/A in annual revenue with weak year-over-year growth of 0.00%.

Key Strengths

ROE48.18%
PEG Ratio0.11

Areas of Concern

Operating Margin0.00%
Cash Position3.69%
Current Ratio0.09
We analyze IZOZF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 46.3/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

D
46.3/100

We analyze IZOZF's fundamental strength across five key dimensions:

Efficiency Score

Weak

IZOZF struggles to generate sufficient returns from assets.

ROA > 10%
-3.68%

Valuation Score

Excellent

IZOZF trades at attractive valuation levels.

PE < 25
-5.42
PEG Ratio < 2
0.11

Growth Score

Weak

IZOZF faces weak or negative growth trends.

Revenue Growth > 5%
0.00%
EPS Growth > 10%
-84.48%

Financial Health Score

Moderate

IZOZF shows balanced financial health with some risks.

Debt/Equity < 1
-0.59
Current Ratio > 1
0.09

Profitability Score

Weak

IZOZF struggles to sustain strong margins.

ROE > 15%
48.18%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is IZOZF Expensive or Cheap?

P/E Ratio

IZOZF trades at -5.42 times earnings. This suggests potential undervaluation.

-5.42

PEG Ratio

When adjusting for growth, IZOZF's PEG of 0.11 indicates potential undervaluation.

0.11

Price to Book

The market values Izotropic Corporation at -2.56 times its book value. This may indicate undervaluation.

-2.56

EV/EBITDA

Enterprise value stands at -5.50 times EBITDA. This is generally considered low.

-5.50

How Well Does IZOZF Make Money?

Net Profit Margin

For every $100 in sales, Izotropic Corporation keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $48.18 in profit for every $100 of shareholder equity.

48.18%

ROA

Izotropic Corporation generates $-3.68 in profit for every $100 in assets, demonstrating efficient asset deployment.

-3.68%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

IZOZF converts -6.28% of its market value into free cash.

-6.28%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-5.42

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.11

vs 25 benchmark

P/B Ratio

Price to book value ratio

-2.56

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.59

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.09

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.48

vs 25 benchmark

ROA

Return on assets percentage

-3.68

vs 25 benchmark

ROCE

Return on capital employed

0.47

vs 25 benchmark

How IZOZF Stacks Against Its Sector Peers

MetricIZOZF ValueSector AveragePerformance
P/E Ratio-5.4229.20 Better (Cheaper)
ROE48.18%684.00% Weak
Net Margin0.00%-52872.00% (disorted) Weak
Debt/Equity-0.590.38 Strong (Low Leverage)
Current Ratio0.094.00 Weak Liquidity
ROA-367.80%-19764.00% (disorted) Weak

IZOZF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Izotropic Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

0.00%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-16.13%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

72.45%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ